GFAP and amyloidosis: Previous studies in mouse amyloid models of AD have shown that MW151 administration causes a reduction in brain levels of the proinflammatory cytokine IL-1® and astrocyte activation as quantified by GFAP positivity, with no effect on underlying plaque burden [7, 16].